Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy

NCT00165880 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT00165880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00165880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy
Lead sponsor
Eisai Limited
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2004
Completion date
September 30, 2007
Enrollment
62 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer